Skip to main content

Recombinant Human DCBLD2/ESDN Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6269-DC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
6269-DC-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human DCBLD2/ESDN protein
Gln67-Ala528, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

No results obtained: Gln67 predicted, sequencing might be blocked

Predicted Molecular Mass

51.9 kDa

SDS-PAGE

80-90 kDa, reducing conditions

Activity

Measured by its ability to inhibit proliferation/survival of IEC-18 rat small intestinal epithelial cells.
The ED50 for this effect is 0.7-2.8 μg/mL.

Formulation, Preparation and Storage

6269-DC
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 300 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: DCBLD2/ESDN

DCBLD2 (discoidin, CUB, and LCCL domain containing protein 2), also known as CLCP1 and ESDN, is a 100-130 kDa glycoprotein that bears structural resemblance to the Neuropilin family of molecules. Mature human DCBLD2 is a type I transmembrane protein that consists of a 462 amino acid (aa) extracellular region (ECD), a 21 aa transmembrane segment, and a 226 aa cytoplasmic domain (1, 2). Within the ECD, human DCBLD2 shares approximately 88% aa sequence identity with mouse and rat DCBLD2. Alternative splicing generates an isoform that contains a 14 aa insertion in the cytoplasmic domain. DCBLD2 is expressed on vascular smooth muscle cells (VSMC), particularly in regions of arteriosclerosis and vascular injury (2, 3). It is up‑regulated on PDGF-BB stimulated VSMC and inhibits PDGF‑BB induced VSMC proliferation and migration (2‑4). It is also expressed on platelets and inhibits clot formation in a zebrafish model of thrombosis (5). Compared to normal tissue, DCBLD2 expression is down‑regulated in some gastric and neuroendocrine tumors but is up‑regulated in some metastatic lung cancers (1, 6, 7). It can be tyrosine phosphorylated in response to EGF R signaling and can inhibit colony formation and tumor cell invasiveness (6, 8, 9). Its direct association with Semaphorin 4B induces DCBLD2 degradation (10).

References

  1. Koshikawa, K. et al. (2002) Oncogene 21:2822.
  2. Kobuke, K. et al. (2001) J. Biol. Chem. 276:34105.
  3. Sadeghi, M.M. et al. (2007) Am. J. Transplant. 7:2098.
  4. Guo, X. et al. (2009) J. Biol. Chem. 284:29376.
  5. O’Connor, M.N. et al. (2009) Blood 113:4754.
  6. Kim, M. et al. (2008) Mol. Cancer Res. 6:222.
  7. Hofsli, E. et al. (2008) Br. J. Cancer 99:1330.
  8. Chen, Y. et al. (2007) Proteomics 7:2384.
  9. Orso, F. et al. (2008) FASEB J. 22:2702.
  10. Nagai, H. et al. (2007) Oncogene 26:4025.

Long Name

Discoidin, CUB and LCCL Domain Containing 2/Endothelial and Smooth Muscle Cell-derived Neuropilin-li

Alternate Names

CLCP1, ESDN

Entrez Gene IDs

131566 (Human); 73379 (Mouse); 155696 (Rat)

Gene Symbol

DCBLD2

UniProt

Additional DCBLD2/ESDN Products

Product Documents for Recombinant Human DCBLD2/ESDN Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human DCBLD2/ESDN Protein, CF

For research use only

Loading...
Loading...
Loading...